Life Sciences Intellectual Property Review (subscription)LSPN North America: CRISPR patent pool may emerge, says RegeneronLife Sciences Intellectual Property Review (subscription)There has been speculation over whether a patent pool for CRISPR licensin… Continue reading
|
BRIEF-Medicenna’s Immunotherapy phase 2B trial underway using Brainlab drug delivery technology
Reuters OTTAWA, June 8 Canadian housing starts dipped in May as construction intentions fell in the major cities of Toronto and Vancouver, data from the Canada Mortgage and Housing Corporation showed on Thursday. |
|
BRIEF-Medicenna’s Immunotherapy phase 2B trial underway using …
Reuters WASHINGTON, June 8 As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc … |
Medical Xpress |
Stem cell treatment for lethal STAT1 gene mutation produces mixed results
Medical Xpress Researchers report the first-ever study assessing how patients with “gain of function” mutation of the STAT1 gene respond to stem cell transplantation. It involved 15 young patients from nine different countries, each suffering a range of complications … |
Medical Xpress |
Stem cell treatment for lethal STAT1 gene mutation produces mixed results
Medical Xpress Researchers report the first-ever study assessing how patients with “gain of function” mutation of the STAT1 gene respond to stem cell transplantation. It involved 15 young patients from nine different countries, each suffering a range of complications … |
Xconomy |
Harvard Biotech Spinout Lands $10M to Make Platelets From Stem Cells
Xconomy Karlsson’s startup aims to bring hospitals an alternative: platelets produced as needed from stem cells. Platelet BioGenesis, a spinout from Harvard University and Brigham and Women’s Hospital, now has $10 million from a Series A round of funding to … |
PharmaTimes |
Novartis’ CAR–T shows durable response in lymphoma patients
PharmaTimes Novartis’ closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR–T cell therapy in a mid-stage trial. Findings from an interim analysis of the multicentre Phase II JULIET study show a three-month overall … |
Motherboard |
CRISPR Is Not Accurate Enough to Save Us Yet
Motherboard And it’s ubiquity isn’t surprising because CRISPR is one of the biggest scientific discoveries of our time. It tremendously improves upon earlier gene-editing techniques because it’s fast, cheap, and accurate. Or so we thought. A new study published … |